Trial reportBMC anesthesiology2025
A randomized trial evaluating hemodynamics during minor hepatectomy under general anesthesia combined with thoracic epidural anesthesia: remimazolam versus propofol.
Trial report in BMC anesthesiology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT06565715 (Effect of Remazolam on Hemodynamics During Hepatectomy Under General Anesthesia Combined With Thoracic Epidural Anesthesia), which is not on this map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Effect of Remazolam on Hemodynamics During Hepatectomy Under General Anesthesia Combined With Thoracic Epidural Anesthesia
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
backgroundHemodynamic instability is common during hepatectomy under general anesthesia combined with thoracic epidural anesthesia, along with intraoperative low central venous pressure (LCVP). We hypothesized that remimazolam-based anesthesia would improve hemodynamic instability compared to propofol-based anesthesia.
methodsThe patients undergoing elective hepatectomy under general anesthesia combined with thoracic epidural anesthesia were enrolled and randomly allocated to either group R (remimazolam anesthesia) or group P (propofol anesthesia). The hemodynamic instability was evaluated by the hemodynamic instability scores (HI-score) at induction period, during hepatectomy and hemostasis. The advanced hemodynamic parameters (cardiac index CI, system vascular resistance index SVRI) were recorded. The secondary outcomes including length of PACU stay, changes in hemoglobin level, major cardiovascular events within postoperative 3 days, length of hospital stay, postoperative ambulation time, and time to first flatus were also documented.
resultsA total of 72 subjects were randomized, and 33 ones under minor hepatectomy surgery in each group were analyzed finally. There was significant hemodynamics instability in both groups, however, the total HI-score was significantly lower in group R (22.8 ± 2.1) than group P (33.0 ± 4.1, P = 0.029). Further analysis demonstrated that the HI-scores were also lower in group R than group P during induction period (11.9 ± 1.0 vs. 22.6 ± 4.2, P = 0.017), hepatectomy period (23.2 ± 3.2 vs. 38.5 ± 6.0, P = 0.027) and hemostasis period (22.2 ± 2.8 vs. 33.5 ± 3.8, P = 0.019). Nevertheless, compared with propofol-based anesthesia, remimazolam-based anesthesia did not reduce incidence of major cardiovascular events and length of hospital stay (P > 0.05).
conclusionsWhen compared with propofol-based anesthesia, remimazolam-based anesthesia has better intraoperative hemodynamic stability during minor hepatectomy surgery under combined general-epidural anesthesia. However, this improved hemodynamics may not necessarily translate into better perioperative outcomes.
trial registrationRegistered at ClinicalTrials.gov (Registration No. NCT06565715 Principal investigator Jun Zhang Date of registration 08/21/2024 https://clinicaltrials.gov/study/NCT06565715?term=NCT06565715&rank=1 ).
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.